Compare ACAD & AAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACAD | AAP |
|---|---|---|
| Founded | 1993 | 1929 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto & Home Supply Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.6B |
| IPO Year | 2000 | 2002 |
| Metric | ACAD | AAP |
|---|---|---|
| Price | $20.83 | $49.63 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 22 | 17 |
| Target Price | $30.55 | ★ $53.50 |
| AVG Volume (30 Days) | ★ 1.5M | 1.4M |
| Earning Date | 05-06-2026 | 05-21-2026 |
| Dividend Yield | N/A | ★ 1.79% |
| EPS Growth | 69.12 | ★ 113.01 |
| EPS | 0.02 | ★ 0.73 |
| Revenue | $726,437,000.00 | ★ $8,601,000,000.00 |
| Revenue This Year | $18.80 | $0.35 |
| Revenue Next Year | $11.70 | $2.51 |
| P/E Ratio | $1,029.50 | ★ $67.93 |
| Revenue Growth | ★ 40.45 | N/A |
| 52 Week Low | $19.69 | $37.89 |
| 52 Week High | $28.35 | $70.00 |
| Indicator | ACAD | AAP |
|---|---|---|
| Relative Strength Index (RSI) | 41.42 | 40.42 |
| Support Level | $20.06 | $49.18 |
| Resistance Level | $22.64 | $53.82 |
| Average True Range (ATR) | 0.79 | 2.46 |
| MACD | -0.17 | -0.85 |
| Stochastic Oscillator | 18.95 | 21.10 |
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
Advance Auto Parts is a leading auto-parts retailer in North America with more than 4,000 store and branch locations. About half of the firm's sales are geared toward the professional channel, with the remaining sales in the do-it-yourself market. Through its vast store footprint and distribution network, Advance manages thousands of stock-keeping units for various vehicle makes and models. The retailer primarily competes on inventory availability and service speed, making the operating efficiency of its hub-and-spoke distribution model critical to meeting customer needs.